What is the 13F Pro Quality Score for CVM?

13F Pro ranks CEL SCI CORP (CVM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CVM's current score at https://13fpro.ai/research/CVM (free sign-up required for the full ranking).

Where does 13F Pro source CVM data?

All CEL SCI CORP fundamentals and ownership data come directly from SEC EDGAR. CEL SCI CORP files with the SEC under CIK 725363. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CVM in?

CEL SCI CORP (CVM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CVM research updated on 13F Pro?

CVM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CEL SCI CORP(CVM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 725363 CVM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CVM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CEL SCI CORP (CVM), a Healthcare sector company. CVM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.0m in revenue. Based on the latest XBRL financial filings (Q2 2026), CEL SCI CORP reports net income of $-5.5M, free cash flow of $-4.0M. Top institutional holders of CVM by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MAI Capital Management, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CVM trades on the NYSE exchange and files with the SEC under CIK 725363. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CEL SCI CORP directly from SEC EDGAR.

Net Income

Q2 2026

$-5.5M

Free Cash Flow

Q2 2026

$-4.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY14 $264.0KFY22 —FY23 —FY25 —

Net Income

+21.5% YoY

$-25.4MFY 2025

FY14 $-27.4MFY22 $-36.7MFY23 $-32.4MFY25 $-25.4M

Operating Income

+21.2% YoY

$-24.8MFY 2025

FY14 $-25.7MFY22 $-36.1MFY23 $-31.5MFY25 $-24.8M

EPS (Diluted)

-758.9% YoY

$-6.27FY 2025

FY14 $-0.49FY22 $-0.87FY23 $-0.73FY25 $-6.27

Total Assets

-7.8% YoY

$28.2MFY 2025

FY14 $19.2MFY22 $50.5MFY23 $30.5MFY25 $28.2M

Total Debt

$8.0MFY 2025

FY14 —FY22 —FY23 —FY25 $8.0M

Op. Cash Flow

+25.1% YoY

$-17.1MFY 2025

FY14 $-22.9MFY22 $-18.2MFY23 $-22.8MFY25 $-17.1M

Metric	FY 2025	FY 2023	FY 2022	FY 2014	FY 2013	FY 2012
Revenue	—	—	—	$264.0K +65.5%	$159.6K -37.3%	$254.6K
Net Income	$-25.4M +21.5%	$-32.4M +11.8%	$-36.7M -34.2%	$-27.4M -198.3%	$-9.2M +40.7%	$-15.5M
Operating Income	$-24.8M +21.2%	$-31.5M +12.7%	$-36.1M -40.5%	$-25.7M -29.2%	$-19.9M -15.2%	$-17.2M
EPS (Diluted)	$-6.27 -758.9%	$-0.73 +16.1%	$-0.87 -77.6%	$-0.49 +25.8%	$-0.66 +15.4%	$-0.78
Total Assets	$28.2M -7.8%	$30.5M -39.6%	$50.5M +162.7%	$19.2M +77.4%	$10.8M -32.5%	$16.1M
Total Debt	$8.0M	—	—	—	—	—
Operating Cash Flow	$-17.1M +25.1%	$-22.8M -25.3%	$-18.2M +20.4%	$-22.9M -69.2%	$-13.5M -11.1%	$-12.2M

AI Insight: CVM Financial Trends

Net losses narrowing and operating cash burn stabilizing, though company remains pre-revenue and debt emerged in Q3 2025.

• Net loss improved from $7M per quarter (Q2-Q4 2024) to $5M in Q4 2025 and Q1 2026—a 29% reduction.

• Operating loss tightened from $7M (Q2, Q4 2024) to $5M (Q4 2025, Q1 2026), showing margin discipline.

• Operating cash burn stabilized at $4–5M quarterly; no material deterioration despite pre-revenue stage.

⚠ Debt appeared in Q3 2025 ($8M) with no corresponding revenue generation; balance sheet structure unclear.

⚠ Equity volatile ($8M–$16M range); cumulative losses eroding shareholder base with no revenue inflection visible.

AI Insight: CVM Ratio Trends

CelSci's profitability metrics collapsed into deep negative territory in Q4 2025, with ROA plunging to -95.6% amid sustained operating losses.

• ROE deteriorated sharply from -152.9% in Q3 2025 to -196.4% in Q4 2025, signaling accelerating shareholder value destruction.

• ROA worsened from -86.7% in Q3 2025 to -95.6% in Q4 2025, indicating deepening asset inefficiency and mounting losses.

⚠ Severe consecutive quarterly losses drive negative returns; Q1 2026 data unavailable—clarify recovery status or continued deterioration.

⚠ Debt-to-equity at 0.50 in Q3 2025; assess balance sheet sustainability under persistent operating losses.

Get alerted when CVM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CEL SCI CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CVM

VANGUARD CAPITAL MANAGEMENT LLC
$782.1K243,645 sh
MAI Capital Management
$293.0K91,280 sh
GEODE CAPITAL MANAGEMENT, LLC
$274.0K85,311 sh
VANGUARD FIDUCIARY TRUST CO
$157.4K49,036 sh
BlackRock, Inc.
$138.9K43,261 sh
BANK OF AMERICA CORP /DE/
$131.6K40,997 sh
RENAISSANCE TECHNOLOGIES LLC
$115.2K35,890 sh
US BANCORP \DE\
$96.0K29,907 sh
STATE STREET CORP
$87.5K27,270 sh
XTX Topco Ltd
$72.4K22,556 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$782.1K	243,645
MAI Capital Management	$293.0K	91,280
GEODE CAPITAL MANAGEMENT, LLC	$274.0K	85,311
VANGUARD FIDUCIARY TRUST CO	$157.4K	49,036
BlackRock, Inc.	$138.9K	43,261
BANK OF AMERICA CORP /DE/	$131.6K	40,997
RENAISSANCE TECHNOLOGIES LLC	$115.2K	35,890
US BANCORP \DE\	$96.0K	29,907
STATE STREET CORP	$87.5K	27,270
XTX Topco Ltd	$72.4K	22,556

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CVM on your watchlist

Track score changes the day CEL SCI CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CVM a good stock to buy?

13F Pro's AI-powered analysis of CEL SCI CORP (CVM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVM are available on the CVM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CVM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CEL SCI CORP's investment landscape.